The possibility of stem cells application in kidney transplantation: experimental studies (literature review)


  • A.S. Voroniak State Institution “O.O. Shalimov National Institute of Surgery and Transplantology” of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
  • R.O. Zograbyan State Institution “O.O. Shalimov National Institute of Surgery and Transplantology” of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine



kidney transplantation, stem cells, induction therapy, renal failure, review


The long-term survival of kidney allografts remains unsatisfactory. The most common cause of graft loss is chronic kidney transplant rejection, which encourages us to actively explore new possible immunosuppressive regimens. Studies of stem cell use in animal models with renal insufficiency show better results in the postoperative period and provide an opportunity for clinical trials in the context of creating an alternative induction immunosuppressive therapy in kidney transplantation. A literature analysis of the preclinical efficacy of mesenchymal stem cells in chronic renal failure and renal allotransplantation in laboratory animals revealed their unique potential in improving the function and repair of damaged kidneys, as well as the presence of immunosuppressive effects, including inhibition of T-cell proliferation, inhibition of the maturation of dendritic cells and induction of regulatory T-cells. They may improve the long-term results of kidney allotransplantation, but this requires further researches.


Neuen BL, Chadban SJ, Demaio AR, Johnson DW, Perkovic V. Chronic kidney disease and the global NCDs agenda. BMJ Glob Health. 2017 Jul 6;2(2):e000380. doi:10.1136/bmjgh-2017-000380.

Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One. 2016 Jul 6;11(7):e0158765. doi:10.1371/journal.pone.0158765.

Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011 Oct;11(10):2093-109. doi:10.1111/j.1600-6143.2011.03686.x.

Coemans M, Süsal C, Döhler B, et al M. Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. Kidney Int. 2018 Nov;94(5):964-973. doi:10.1016/j.kint.2018.05.018.

Eirin A, Lerman LO. Mesenchymal stem cell treatment for chronic renal failure. Stem Cell Res Ther. 2014 Jul 4;5(4):83. doi:10.1186/scrt472.

Hoogduijn MJ, Popp FC, Grohnert A, et al; MISOT Study Group. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation. 2010 Jul 27;90(2):124-6. doi:10.1097/TP.0b013e3181ea4240.

Rosenberg ME. Cell-based therapies in kidney disease. Kidney Int Suppl (2011). 2013 Dec;3(4):364-367. doi:10.1038/kisup.2013.78.

Franquesa M, Herrero E, Torras J, et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev. 2012 Nov 20;21(17):3125-35. doi:10.1089/scd.2012.0096.

Hoogduijn MJ, Popp FC, Grohnert A, et al; MISOT Study Group. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation. 2010 Jul 27;90(2):124-6. doi:10.1097/TP.0b013e3181ea4240.

Prodromidi EI, Poulsom R, Jeffery R, et al. Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells. 2006 Nov;24(11):2448-55. doi:10.1634/stemcells.2006-0201.

Reinders ME, de Fijter JW, Rabelink TJ. Mesenchymal stromal cells to prevent fibrosis in kidney transplantation. Curr Opin Organ Transplant. 2014 Feb;19(1):54-9. doi:10.1097/MOT.0000000000000032.

Souidi N, Stolk M, Seifert M. Ischemia-reperfusion injury: beneficial effects of mesenchymal stromal cells. Curr Opin Organ Transplant. 2013 Feb;18(1):34-43. doi:10.1097/MOT.0b013e32835c2a05.

Chen J, Park HC, Addabbo F, et al. Kidney-derived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair. Kidney Int. 2008 Oct;74(7):879-89. doi:10.1038/ki.2008.304.

Tomasoni S, Longaretti L, Rota C, et al. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev. 2013 Mar 1;22(5):772-80. doi:10.1089/scd.2012.0266.

Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol. 2011 Feb;6(2):412-22. doi:10.2215/CJN.04950610.

Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA. 2012 Mar 21;307(11):1169-77. doi:10.1001/jama.2012.316.

Reinders ME, de Fijter JW, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med. 2013 Feb;2(2):107-11. doi:10.5966/sctm.2012-0114.

Casiraghi F, Perico N, Cortinovis M, Remuzzi G. Mesenchymal stromal cells in renal transplantation: opportunities and challenges. Nat Rev Nephrol. 2016 Apr;12(4):241-53. doi:10.1038/nrneph.2016.7.

Méndez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010 Aug 12;466(7308):829-34. doi:10.1038/nature09262.

Choi S, Park M, Kim J, Hwang S, Park S, Lee Y. The role of mesenchymal stem cells in the functional improvement of chronic renal failure. Stem Cells Dev. 2009 Apr;18(3):521-9. doi:10.1089/scd.2008.0097.

Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yañez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant. 2008 Jun;14(6):631-40. doi:10.1016/j.bbmt.2008.01.006.

Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation. 2010 Dec 27;90(12):1312-20. doi:10.1097/TP.0b013e3181fed001.

Zonta S, De Martino M, Bedino G, et al. Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial? Transplant Proc. 2010 May;42(4):1336-40. doi:10.1016/j.transproceed.2010.03.081.

De Martino M, Zonta S, Rampino T, et al. Mesenchymal stem cells infusion prevents acute cellular rejection in rat kidney transplantation. Transplant Proc. 2010 May;42(4):1331-5. doi:10.1016/j.transproceed.2010.03.079.

Ochiya T, Yamamoto Y, Banas A. Commitment of stem cells into functional hepatocytes. Differentiation. 2010 Feb;79(2):65-73. doi:10.1016/j.diff.2009.10.002.

Monteiro BS, Santos BSD, Almeida BL, et al. Adipose tissue derived mesenchymal stem cell transplantation in the treatment of ischemia/reperfusion induced acute kidney injury in rats. Application route and therapeutic window1. Acta Cir Bras. 2018 Nov;33(11):1016-1026. doi:10.1590/s0102-865020180110000008.

Parolini O, Alviano F, Bagnara GP, et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells. 2008 Feb;26(2):300-11. doi:10.1634/stemcells.2007-0594.

Evangelista M, Soncini M, Parolini O. Placenta-derived stem cells: new hope for cell therapy? Cytotechnology. 2008 Sep;58(1):33-42. doi:10.1007/s10616-008-9162-z.

Wolbank S, Stadler G, Peterbauer A, et al. Telomerase immortalized human amnion- and adipose-derived mesenchymal stem cells: maintenance of differentiation and immunomodulatory characteristics. Tissue Eng Part A. 2009 Jul;15(7):1843-54. doi:10.1089/ten.tea.2008.0205.

Chang CJ, Yen ML, Chen YC, et al. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells. 2006 Nov;24(11):2466-77. doi:10.1634/stemcells.2006-0071.

Miki T. Amnion-derived stem cells: in quest of clinical applications. Stem Cell Res Ther. 2011 May 19;2(3):25. doi:10.1186/scrt66.

Parolini O, Alviano F, Bergwerf I, et al. Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. Stem Cells Dev. 2010 Feb;19(2):143-54. doi:10.1089/scd.2009.0404.

Bailo M, Soncini M, Vertua E, et al. Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation. 2004 Nov 27;78(10):1439-48. doi:10.1097/

Avila M, España M, Moreno C, Peña C. Reconstruction of ocular surface with heterologous limbal epithelium and amniotic membrane in a rabbit model. Cornea. 2001 May;20(4):414-20. doi:10.1097/00003226-200105000-00016.

Sankar V, Muthusamy R. Role of human amniotic epithelial cell transplantation in spinal cord injury repair research. Neuroscience. 2003;118(1):11-7. doi:10.1016/s0306-4522(02)00929-6.

Yuge I, Takumi Y, Koyabu K, et al. Transplanted human amniotic epithelial cells express connexin 26 and Na-K-adenosine triphosphatase in the inner ear. Transplantation. 2004 May 15;77(9):1452-4. doi:10.1097/00007890-200405150-00023.

Takashima S, Ise H, Zhao P, Akaike T, Nikaido T. Human amniotic epithelial cells possess hepatocyte-like characteristics and functions. Cell Struct Funct. 2004 Jun;29(3):73-84. doi:10.1247/csf.29.73.

Sakuragawa N, Enosawa S, Ishii T, et al. Human amniotic epithelial cells are promising transgene carriers for allogeneic cell transplantation into liver. J Hum Genet. 2000;45(3):171-6. doi:10.1007/s100380050205.

Rota C, Morigi M, Imberti B. Stem Cell Therapies in Kidney Diseases: Progress and Challenges. Int J Mol Sci. 2019 Jun 7;20(11):2790. doi:10.3390/ijms20112790.

Morigi M, Rota C, Montemurro T, et al. Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. Stem Cells. 2010 Mar 31;28(3):513-22. doi:10.1002/stem.293.

Perico L, Morigi M, Rota C, et al. Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. Nat Commun. 2017 Oct 17;8(1):983. doi:10.1038/s41467-017-00937-2.

Fang TC, Pang CY, Chiu SC, Ding DC, Tsai RK. Renoprotective effect of human umbilical cord-derived mesenchymal stem cells in immunodeficient mice suffering from acute kidney injury. PLoS One. 2012;7(9):e46504. doi:10.1371/journal.pone.0046504.

Di Campli C, Piscaglia AC, Pierelli L, et al. A human umbilical cord stem cell rescue therapy in a murine model of toxic liver injury. Dig Liver Dis. 2004 Sep;36(9):603-13. doi:10.1016/j.dld.2004.03.017.

Zhao W, Li JJ, Cao DY, et al. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol. 2012 Mar 14;18(10):1048-58. doi:10.3748/wjg.v18.i10.1048.

Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009 Jan;15(1):42-9. doi:10.1038/nm.1905.

Reinders ME, Roemeling-van Rhijn M, Khairoun M, et al. Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy. Cytotherapy. 2013 Jun;15(6):663-72. doi:10.1016/j.jcyt.2013.01.010.

Casiraghi F, Azzollini N, Todeschini M, et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant. 2012 Sep;12(9):2373-83. doi:10.1111/j.1600-6143.2012.04115.x.

Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013 Oct 3;13(4):392-402. doi:10.1016/j.stem.2013.09.006.

Pevsner-Fischer M, Morad V, Cohen-Sfady M, et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood. 2007 Feb 15;109(4):1422-32. doi:10.1182/blood-2006-06-028704.

Roemeling-van Rhijn M, Reinders ME, Franquesa M, et al. Human Allogeneic Bone Marrow and Adipose Tissue Derived Mesenchymal Stromal Cells Induce CD8+ Cytotoxic T Cell Reactivity. J Stem Cell Res Ther. 2013 Dec 12;3(Suppl 6):004. doi:10.4172/2157-7633.S6-004.

Roemeling-van Rhijn M, Khairoun M, Korevaar SS, et al. Human Bone Marrow- and Adipose Tissue-derived Mesenchymal Stromal Cells are Immunosuppressive In vitro and in a Humanized Allograft Rejection Model. J Stem Cell Res Ther. 2013 Nov 25;Suppl 6(1):20780. doi:10.4172/2157-7633.S6-001.

Wang Y, Zhang A, Ye Z, Xie H, Zheng S. Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion. Transplant Proc. 2009 Dec;41(10):4352-6. doi:10.1016/j.transproceed.2009.08.072.

Casiraghi F, Azzollini N, Todeschini M, et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant. 2012 Sep;12(9):2373-83. doi:10.1111/j.1600-6143.2012.04115.x.

Le Blanc K, Frassoni F, Ball L, et al; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008 May 10;371(9624):1579-86. doi:10.1016/S0140-6736(08)60690-X.

Ball LM, Bernardo ME, Roelofs H, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 2013 Nov;163(4):501-9. doi:10.1111/bjh.12545.

Hoogduijn MJ, Crop MJ, Korevaar SS, et al. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. Transplantation. 2008 Nov 15;86(9):1283-91. doi:10.1097/TP.0b013e31818aa536.

Eggenhofer E, Renner P, Soeder Y, et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol. 2011 Sep;25(2-3):141-7. doi:10.1016/j.trim.2011.06.002.

Eggenhofer E, Steinmann JF, Renner P, et al. Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts. Transpl Immunol. 2011 Apr 15;24(3):157-63. doi:10.1016/j.trim.2010.12.002.

Ge W, Jiang J, Baroja ML, et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant. 2009 Aug;9(8):1760-72. doi:10.1111/j.1600-6143.2009.02721.x.

Zhang W, Qin C, Zhou ZM. Mesenchymal stem cells modulate immune responses combined with cyclosporine in a rat renal transplantation model. Transplant Proc. 2007 Dec;39(10):3404-8. doi:10.1016/j.transproceed.2007.06.092.

Casiraghi F, Perico N, Remuzzi G. Mesenchymal stromal cells for tolerance induction in organ transplantation. Hum Immunol. 2018 May;79(5):304-313. doi:10.1016/j.humimm.2017.12.008.